Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

Abstract: The present invention relates to an aircraft-utilizing deterioration diagnostic system and provides a technique capable of improving diagnostic efficiency and accuracy when comparing the previous and current aerially-photographed images to diagnose a deteriorated state of a target. The diagnostic system includes: a drone 1 (aircraft) configured to be navigated along a route around a target 5 and having a camera 4 configured to photograph the target 5; and a computer (PC 2 and server 3) configured to control navigation of the aircraft and photographing by the camera 4.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to an aircraft-utilizing deterioration diagnostic system and provides a technique capable of improving diagnostic efficiency and accuracy when comparing the previous and current aerially-photographed images to diagnose a deteriorated state of a target. The diagnostic system includes: a drone 1 (aircraft) configured to be navigated along a route around a target 5 and having a camera 4 configured to photograph the target 5; and a computer (PC 2 and server 3) configured to control navigation of the aircraft and photographing by the camera 4.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.

Abstract: A system for motion analytics includes acceleration sensors and selectively infrared sensors or microphones. The system also includes a processor and display device. The processor identifies test scores obtained by subjects. The processor also computes degrees of similarities in the real-time physical movements between the at least two groups of subjects using the acceleration sensors, and an amount of time during which some subjects among the at least two groups of subject are engaged in communication using the infrared sensors and/or the microphones. Further, the processor analyzes a correlation between the test scores and the degrees of similarities, and between the test scores and the amount of communication time. The processor then predicts an improvement in the test scores based on patterns in the analysis of the correlation. The predicted improvement of the test scores is then displayed on the display device.

Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Abstract: An image recording apparatus (1) causes a recording head (20) to move through a distance corresponding to one half of the recording width of the recording head (20) in a sub-scanning direction each time a recording drum (10) makes one rotation. This, light emitting devices (23, 24) record two line data in advance, and thereafter following light emitting devices (21, 22) record the same line data repeatedly at the same position. This increases the energy of laser light beams given to a recording position on a printing plate (P) to accomplish the recording of an image with reliability. The recording speed is not extremely decreased because not all light emitting devices (21 to 24) are used to make the repeated recordings at the same position on the printing plate (P). Further, the construction of optical systems and driving systems in the image recording apparatus is not complicated.

Abstract: To take a ceremonial photograph including a user himself/herself in a theme park or the like, the user must hand to a third person a camera to ask the photographing. There is a system which can take a picture of a user when the user is in a predetermined position, but the user cannot confirm the picture when the user is being photographed. For the purposes, an image service system includes plural cameras connected to a network, an administration server for accumulating or distributing images taken by the cameras, and a client terminal for displaying the images taken by the cameras. The position of the user and the positions of surrounding cameras located within a predetermined distance from the client terminal are detected automatically. Images including the user can be displayed on the terminal.

Abstract: An object of the invention is to provide a control apparatus and a control method having a simple constitution, which can stably perform switching of optical path in an optical signal exchanger, while suppressing an influence on a control due to the mechanical resonance of tilt mirrors. To this end, the control apparatus of the optical signal exchanger is constituted such that in an optical signal exchanger of three-dimensional type using one set of MEMS mirror arrays, each having a plurality of tilt mirrors arranged on a plane, each tilt mirror having a reflecting surface an angle of which is controllable, when the angle of the MEMS mirror on the optical path is feedback controlled by detecting power of an optical signal output from a specific position, a resonance component removing section that removes a resonance frequency component included in a control signal is shared corresponding to a pair of driving electrodes arranged in a coaxial direction of the MEMS mirror.